Among them, immune checkpoint blockade with antibodies that target cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) is demonstrating dramatic antitumor effects in subsets of patients in a variety of cancer types [13]. Here, PDCD1 is linked to cancer.